• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Study: Boston Scientific CRM batteries beat Medtronic, St. Jude

Study: Boston Scientific CRM batteries beat Medtronic, St. Jude

October 10, 2013 By Arezu Sarvestani

Study: Boston Scientific CRM batteries beat Medtronic, St. Jude

Medical device maker Boston Scientific (NYSE:BSX) touted a new study proclaiming the reliability of the batteries in its implanted defibrillators, which bested devices by Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ) in a clinical study.

Researchers examined nearly 650 "current models" of implantable cardioverter defibrillators, all implanted between Jan. 1, 2008 and Dec. 31, 2010. At about 2.5 years 25% of Medtronic’s devices had already depleted their batteries, compared with 7% of St. Jude’s and 4% of Boston Scientific’s.

At 4 years 33% of Medtronic’s devices needed replacement, compared with 8% of St. Jude’s and 6% of Boston Scientific’s, independent of pacing therapy parameters.

Boston Scientific was quick to tout the news, issuing a press release highlighting the findings and emphasizing the importance of battery life to patient outcomes.

"With improved therapies, the majority of today’s heart failure patients will outlive their implantable device," chief medical officer Dr. Kenneth Stein said in prepared remarks. "As patients live longer, the benefit from longer-lasting devices and fewer replacement surgeries becomes increasingly significant."

The Massachusetts medtech giant has flaunted its ICD batteries in the past, even publicly flogging its rivals over device longevity.

Medtronic in won FDA clearance for its Viva portfolio of cardiac resynchronization defibrillators, touting the devices’ 11-year battery life. Boston Scientific responded with an attack ad proclaiming that the Viva line only lasted 4.6 years in clinical tests, stating "Medtronic just launched their new high-voltage platform. We just have one question… Why another sub 5-year CRT-D?"

Medtronic called the ad "frankly misleading," countering with a "Reality Check" that claimed Medtronic’s ICDs lasted longer in "7 independent studies, including over 10,600 patients at 15 centers."

Boston Scientific has something of a reputation for its CRM battery life, having won European Union and FDA approval to market several of its implants as featuring longevity of up to 10 years. Last year group purchasing organization Novation highlighted the company’s efforts to boost battery life as a must for all implantable device makers.

Earlier this year Boston Scientific released new data showing 9-to-13-year battery life for its ICDs, arising from an analysis of more than 100,000 patients. The data showed that batteries of Boston Scientific single-chamber ICDs, dual-chamber ICDs and CRT-Ds lasted an average of 13.2, 11.5 and 9.2 years, the company said.

The new study, conducted by University of Pittsburgh Medical Center, included 173 Boston Scientific devices, 416 Medtronic devices and 57 St. Jude devices, all implanted at the UPMC facility. The results were published this week in the journal EP EuroPace.

Filed Under: News Well Tagged With: Boston Scientific, Cardiac Rhythm Management, Clinical Trials, Minnesota, stjudemedical

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy